Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy
Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Patients will be treated for 2 consecutive chemo cycles with the study drug for one and
placebo for the other. In addition, patients will receive an injection before the chemo,
either ondansetron (if receiving placebo inhalation) or normal saline) if receiving active
study drug. They will take study medication for 3 days, 4 times daily and fill out VAS scores
before and after doses. Patients will be given rescue medication with each dose.
Phase:
Phase 2
Details
Lead Sponsor:
Rafa Laboratories
Collaborators:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.